Missed the 2020 LEAD Conference? Catch up today with this conference overview from Dr. Shannon Westin.
Conference overview highlights presented by Co-Chair, Dr. Julie Vose
Co-Chair, Julie Brahmer provides conference highlights from this year's virtual meeting
LEAD 2020 Conference overview highlights presented by Co-Chair, Dr. Nina Shah
Here Dr. Pellini highlight key takeaways from the 2020 LEAD Virtual Conference
5 Live - Major conference takeaways from experts in 5 minutes or less. Featuring new content from #ASCO21
William G. Wierda, M.D., Ph.D.; The University of Texas MD Anderson Cancer Center; 5Live; #ASCO2021
Virginia Kaklamani, MD, DSc; UT Health San Antonio, MD Anderson Cancer Center; 5Live; #ASCO2021
Robert L. Coleman, MD; US Oncology Research; 5Live; #ASCO2021
Thomas J. Herzog, MD; University of Cincinnati Cancer Center; 5Live; #ASCO21
Shaji Kumar, MD; Mayo Clinic Rochester, MN; 5Live; #ASCO2021
Robert Orlowski, MD, PhD; The University of Texas MD Anderson Cancer Center; 5Live; #ASCO2021
Susan O'Brien, MD; University of California Irvine; 5Live; #ASCO2021
Ravi Vij, MD, MBA; Washington University School of Medicine; 5Live; #ASCO2021
Nikhil Munshi, MD; Dana-Farber Cancer Institute at Harvard Medical School; 5Live; #ASCO2021
Beyond the Congress: Key Conversations in Hematologic Malignancies from the Summer 2021 Annual Meetings
Ranjana Advani, MD; Stanford University #BtC_ASCO21
Dr. Ranjana Advani shares strategies for Integrating Recently Approved Therapies for B-cell NHL Into Practice.
Sagar Lonial, MD, FACP; Emory University #BtC_ASCO21
Dr. Sagar Lonial reviews Recently Presented Data of Clinical Trials and Standard of Care in Upfront Treatment for MM
John P. Leonard, MD; Weill Cornell Medicine #BtC_ASCO21
Dr. John Leonard discusses Recently Presented Data of Clinical Trials in Patients with NHL.
Jennifer R. Brown, MD, PhD; Dana-Farber Cancer Institute #BtC_ASCO21
Dr. Jennifer Brown reviews Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory CLL.
Selina Luger, MD, FRCPC; University of Pennsylvania #BtC_ASCO21
Dr. Selina Luger discusses Biomarkers and their Implications for Therapy in AML.
Nicole Lamanna, MD; Columbia University #BtC_ASCO21
Dr. Nicole Lamanna discusses Practical Issues in Treating CLL: Sequencing, Oral Adherence, Managing Adverse Events, and MRD Analysis.
Maria-Victoria Mateos, MD, PhD; University of Salamanca #BtC_ASCO21
Dr. Maria-Victoria Mateos discusses Recently Presented Data of Clinical Trials and Standard of Care in Relapsed/Refractory MM
Gail Roboz, MD; Weill Cornell Medicine #BtC_ASCO21
Dr. Gail Roboz presents on Personalizing Therapy for Adult Patients with ALL.
Nina Shah, MD; UCSF Health #BtC_ASCO21
Dr. Nina Shah reviews Considerations for the Community Provider in Using CAR T-Cell Therapies for MM